Clearmind Medicine
CMND
5 hedge funds and large institutions have $115K invested in Clearmind Medicine in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
67% more funds holding
Funds holding: 3 → 5 (+2)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
55% less capital invested
Capital invested by funds: $256K → $115K (-$141K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$13.5K |
| 2 |
HF
HRT Financial
New York
|
+$6.75K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$6.75K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
-$20.3K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$3.15K |
CMND Hedge Fund Activity: Q2 2023 in Review
5 of the 6,352 institutional investors tracked by Wall St. Rank reported a position in Clearmind Medicine (CMND) for Q2 2023, worth a combined $115K — down 55% from $256K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new CMND positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $13.5K. The largest seller was AdvisorShares Investments, cutting an estimated $20.3K.
- 5 institutional investors held Clearmind Medicine (CMND) as of Q2 2023, up from 3 in Q1 2023.
- Funds reported $115K of Clearmind Medicine stock for Q2 2023, down 55% quarter-over-quarter.
- 2 funds opened new Clearmind Medicine positions in Q2 2023 and 0 closed out, a net change of +2 holders.
- The largest Clearmind Medicine buyer in Q2 2023 was Citadel Advisors, an estimated $13.5K added.
- The largest Clearmind Medicine seller in Q2 2023 was AdvisorShares Investments, an estimated $20.3K sold.
Based on aggregated 13F filings for Q2 2023.